Quality control of Shuanghuanglian preparations using an effect-constituent index / 药学学报

We established a quality evaluation method for Shuanghuanglian preparations based on an effect-constituent index (ECI), which is guided by the clinical efficacy of Shuanghuanglian and a dose-efficacy correlation. An HPLC method was used to establish the quantitative fingerprint of Shuanghuanglian from different manufacturers and to determine the content of 10 fingerprint components, including baicalin, chlorogenic acid, forsythin, galuteolin, wogonin, forsythoside A, luteolin, caffeic acid, baicalein, and scutellarin. Using Staphylococcus aureus as biological model, the potency of Shuanghuanglian preparations was determined by antibiotic microbial assay. Using the method of PLC-DA, the efficacious antibacterial components were screened by "dose-efficacy" correlation analysis. According to the antibacterial potency and content of the antibacterial ingredients, combined with the method of the custom weight coefficient, ECI was calculated and verified. The results show that the antibacterial ECI can facilitate evaluation of the efficacy of Shuanghuanglian based on the composition of its contents, providing a new method for the quality control of traditional Chinese medicine.

[Study on prenatal diagnosis using fluorescence quantitative polymerase chain reaction for congenital toxoplasmosis].

OBJECTIVE: To investigate prenatal diagnosis and treatment of toxoplasmosis in fetuses with fluorescence quantitative polymerase chain reaction (FQ-PCR) technique. METHODS: Of the 70 pregnant women with toxoplasma (TOX) DNA positive, TOX DNA in amniotic fluid and/or fetal umbilical cord blood was detected with FQ-PCR technique to diagnose fetal infection. 48 ones were given routine treatment with spiramycin for 2 therapy periods. Ultrasound examination were undertaken in all of pregnant women to monitor fetal growth. RESULTS: Of the 70 cases with TOX DNA positive, TOX DNA was detected in 21 fetuses. TOX DNA positive rates were similar in amniotic fluid and umbilical cord blood. The higher the TOX DNA, the higher fetal infectious rate. Fetal infectious rate was lower in treatment group (21%) than that in control group (50%), there was a statistically difference between two groups. CONCLUSIONS: Maternal TOX infection may cause fetal damage. Detection of TOX-DNA in amniotic fluid with FQ-PCR technique can diagnose fetal toxoplasmosis exactly. Treatment in pregnant period may decrease intrauterine infection rate.